Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides …………… Kasuya T, Kugimiya A. Nucleic Acid Ther. 2018 Aug 10. PubMed 00
Studies of Impending Oligonucleotide Therapeutics in Simulated Biofluids …………… Domljanovic I, Hansen AH, Hansen LH, Klitgaard JK, Taskova M, Astakhova K. Nucleic Acid Ther. 2018 Aug 14. PubMed 00
Characterization of the Activity and Distribution of a 2′-O-Methoxyethyl-modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease …………… Donner AJ, Bell TA, Greenlee S, Graham MJ, Crooke RM. Nucleic Acid Ther. 2018 Aug 22. PubMed 00
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies …………… Janas MM, Harbison CE, Perry VK, Carito B, Sutherland JE, Vaishnaw AK, Keirstead ND, Warner G. Toxicol Pathol. 2018 Aug 23:192623318792537. PubMed 00